DMYD B — Diamyd Medical AB Share News
0.000.00%
Last trade - 00:00- SEK156.53m
- -SEK93.80m
- SEK0.48m
Brief: Diamyd Medical Accelerates Primary Efficacy Readout By 9 Months
Brief: Anders Essen-Möller Elected Chairman Of Diamyd Medical Board
Brief: Diamyd Medical Jun-Aug Operating Loss SEK 46.9 Mln
Brief: Diamyd Medical Gets Patent For Insulin Antigen Treatment
Brief: Eurasia To Grant Precision Medicine Patent To Diamyd Medical
Brief: Diamyd Medical Q3 Net Loss SEK 44 Mln
Brief: Diamyd Medical Appoints Niklas Axelsson As CFO
Brief: Diamyd Medical Expands Completed Rights Issue With Directed New Issue Of SEK 41.6 Mln
Brief: Diamyd Medical Announces Preliminary Outcome Of Rights Issue
Brief: Diamyd Medical Says Co's Rights Issue Has Been Preliminarily Subscribed To 95%, Raising Approximately SEK 198 Million
Brief: Diamyd Medical To Get Grant Precision Medicine EPO Patent
Brief: Diamyd Medical Says Australia Grants Co's Patent For Novel Antigen Combination In Autoimmune Diabetes Treatment
Brief: Diamyd Medical Q2 Net Loss SEK 44.9 Mln
Brief: Diamyd Medical Gets Patent Granted In Mexico
Brief: Diamyd Medical's CFO To Leave In 2025
Brief: Diamyd Medical To Get $1.75 Mln In Collaboration Support From Breakthrough T1D
Brief: Diamyd Medical Q1 Net Loss Widens To SEK 36.2 Mln
Brief: Diamyd Medical: South Korea To Grant Precision Medicine Patent
Brief: Diamyd Medical Confirms Key Advances Toward Accelerated Approval For Diamyd Following FDA Type C Meeting